Please assess the completion status of the following clinical trial:

Trial Title: A Study of IBI306 in Participants With Hypercholesterolemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~1. Males and females ≥ 18 to ≤ 75 years of age~2. Diagnosis of hypercholesterolemia~3. LDL cholesterol ≥ 70 mg/dl (1.8mmol/L)~4. Very high or high cardiovascular risk~5. TG≤500 mg/dL(5.64 mmol/L)~Exclusion criteria~1. Uncontrolled hypertension~2. Uncontrolled hyperthyroidism or hypothyroidism~3. Severe renal dysfunction~4. Known sensitivity to any of the products to be administered during dosing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- IBI306 (Type: EXPERIMENTAL): IBI306 administered subcutaneously (SC)
- Placebo (Type: PLACEBO_COMPARATOR): administered subcutaneously (SC)

Based on this trial design, predict the completion outcome and termination type (if applicable).